Zifi CV 100 DT Tablet is a combination antibiotic formulation containing Cefixime 100 mg and Clavulanic Acid 62.5 mg, designed to treat a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, effectively targeting both Gram-positive and Gram-negative organisms. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefixime by preventing enzymatic degradation of the antibiotic, thereby overcoming resistance mechanisms in beta-lactamase producing bacteria. This synergistic combination is indicated for the management of respiratory tract infections, urinary tract infections, otitis media, skin and soft tissue infections, and other susceptible bacterial infections. The tablet formulation is designed for oral administration, offering convenience and improved patient compliance. Zifi CV 100 DT should be used as directed by a healthcare professional, with dosage adjustments based on infection severity and patient-specific factors such as renal function. Common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and alterations in liver enzyme levels. Caution is advised in patients with a history of penicillin or cephalosporin allergy. This medication should be stored in a cool, dry place, away from direct sunlight, and kept out of reach of children.